Marjan KAMALPOUR, Masoud FEREİDONİ, Ali MOGHİMİ

Effects of intrathecal carbenoxolone treatment on nociception and analgesia in rat

Background: Gap junctions (GJ) are important in pain signalling at the spinal cord level. Aims: The aim of this investigation was to study the effects of GJ on nociception and the analgesic/hyperalgesic effects of morphine fol- lowing administration of carbenoxolone as a GJ blocker. Male Wistar rats (200-250 g) were divided into three groups: saline i.p., 10 mg/kg and 1 μg/kg i.p. morphine, each with two subgroups. One was treated intrathecally with saline and the other with carbenoxolone.Study Design: Animal experiment. Methods: The thermal nociception threshold was measured prior to and after injections using the tail flick test. Chemical nociception assessment was conducted using a 0.05-mL subplantar injection of 2.5% formalin. Results: Both formalin-induced neurogenic and inflammatory noci- ception were reduced in the [saline i.p./carbenoxolone i.t.] and [mor- phine 1 μg/kg, i.p./carbenoxolone i.t.] subgroups (p

PDF

___

1. Bradesi S. Role of spinal cord glia in the central processing of peripheral pain perception. Neurogastroenterol Motil 2010;22:499-511. [CrossRef]
2.Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009;139:267-83. [CrossRef]
3.Daehyun Jo, Chapman CR, Alan RL. Glial mechanisms of neuropathic pain and emerging interventions. Korean J Pain 2009;22:1-15. [CrossRef]
4.Bennett MVL. Gap junctions as electrical synapses. J Neurocytol 1997;26:349-66. [CrossRef]
5.Meşe G, Richard G, White TW. Gap junctions: basic structure and func- tion. J Invest Dermatol 2007;127:2516-24. [CrossRef]
6.Juszczak GR, Swiergiel AH. Properties of gap junction blockers and their behavioral, cognitive and electrophysiological effects: animal and human studies. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:181-98. [CrossRef]
7. Söhl G, Maxeiner S, Willecke K. Expression and functions of neuronal gap junctions. Nat Rev Neurosci 2005;6:191-200. [CrossRef]
8. Spataro LE, Sloane EM, Milligan ED, Wieseler-Frank J, Schoeniger D, Jekich BM, et al. Spinal gap junctions: potential involvement in pain facilitation. J Pain 2004;5:392-405. [CrossRef]
9. Schomberg D, Olson JK. Immune responses of microglia in the spinal cord: contribution to pain states. ExpNeurol 2012;234:262-70. [CrossRef]
10. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci 2001;24:450-4. [CrossRef]
11. Ren K. Emerging role of astroglia in pain hypersensitivity. Jpn Dent Sci Rev 2010;46:86-92. [CrossRef]
12. Gao YJ, Ji RR. Targeting astrocyte signaling for chronic pain. Neuro- therapeutics 2010;7:482-93. [CrossRef]
13. Roh DH, Yoon SY, Seo HS, Kang SY, Han HJ, Beitz AJ, et al. Intrathe- cal injection of carbenoxolone, a gap junction decoupler, attenuates the induction of below-level neuropathic pain after spinal cord injury in rats. Exp Neurol 2010;224:123-32. [CrossRef]
14. Chiang CY, Li Z, Dostrovsky JO, Sessle BJ. Central sensitization in medullary dorsal horn involves gap junctions and hemichannels. Neuro- report 2010;21:233-7. [CrossRef]
15. Suzuki M, Narita M, Nakamura A, Suzuki T. Role of gap junction in the expression of morphine-induced antinociception. Eur J Pharmacol 2006;535:169-71. [CrossRef]
16. Zimmermann M. Ethical considerations in relation to pain in animal ex- perimentation. Acta Physiol Scand Suppl 1986;554: 221-33.
17. Abbasi Z, Fereidoni M, Behnam-Rassouli M. Effects of intrathecal ad- ministration of genipin on pain and morphine induced analgesia in rats. Physiol Pharmacol 2013;17:164-75.
18. Yaksh TL, Rudy TA. Narcotic analgestics: CNS sites and mecha- nisms of action as revealed by intracerebral injection techniques. Pain 1978;4:299-359. [CrossRef]
19. DAmour FE, Smith DL. A method for determining loss of pain sensa- tion. J Pharmacol Exp Ther 1941;72:74-8.
20. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 1977;4:161-74. [CrossRef]
21. Nevin RL. Investigating channel blockers for the treatment of multiple sclerosis: considerations with mefloquine and carbenoxolone. J Neuro- immunol 2012;243:106-7. [CrossRef]
22. Hald A, Nedergaard S, Hansen RR, Ding M, Heegaard AM. Differential activation of spinal cord glial cells in murine models of neuropathic and cancer pain. Eur J Pain 2009;13:138-45. [CrossRef]
23. Svensson CI, Brodin E. Spinal astrocytes in pain processing: non-neuro- nal cells as therapeutic targets. MolInterv 2010;10:25-38. [CrossRef]
24. Alvarez-Maubecin V, Garcia-Hernandez F, Williams JT, Van Bock- staele EJ. Functional coupling between neurons and glia. J Neurosci 2000;20:4091-8.
25. Ji RR, Kawasaki Y, Zhuang ZY, Wen YR, Decosterd I. Possible role of spinal astrocytes in maintaining chronic pain sensitization: review of current evidence with focus on bFGF/JNK pathway. Neuron Glia Biol 2006;2:259-69. [CrossRef]
26. Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, et al. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 2007;47:1008-25. [CrossRef]
27. Mogil JS. Animal models of pain: progress and challenges. Nat Rev Neurosci 2009;10:283-94. [CrossRef]
28. Basbaum AI, Jessell TM. The perception of pain. In: Kandel ER, Schwartz JH, Jessell TM, editors. Principles of neural science. 4th Ed. New York: McGraw-Hill Companies; 2000:404-20.
29. Kuner R. Central mechanisms of pathological pain. Nat Med 2010;16:1258-66. [CrossRef]
30. Sinatra R, Jahr JS, Watkins-Pitchford JM. The essence of analgesia and analgesics. Cambridge: Cambridge University Press; 2010. [CrossRef]
31. Hameed H, Hameed M, Christo PJ. The effect of morphine on glial cells as a potential therapeutic target for pharmacological development of an- algesic drugs. Curr Pain Headache Rep 2010;14:96-104. [CrossRef]
32. Ruscheweyh R, Sandkühler J. Opioids and central sensitisation: II. Induction and reversal of hyperalgesia. Eur J Pain 2005;9:149-52. [CrossRef]
33. Angst MS, Clark DJ. Opioid-induced hyperalgesia: a qualitative system- atic review. Anesthesiology 2006;104:570-87. [CrossRef]
34. Jones T. The management of opioid-induced hyperalgesia. Brit J Clin- Pharmaco 2010;2:153-6.
35. Kielian T. Glial connexins and gap junctions in CNS inflammation and disease. J Neurochem 2008;106:1000-16. [CrossRef]
36. Crain SM, Shen KF. Neuraminidase inhibitor, oseltamivir blocks GM1 ‎ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, ‎enhances opioids analgesia and attenuates tolerance in mice. Brain Res 2004;995:260-6. [CrossRef]